Three supercharged income stocks -- sporting an average yield of 8.63% -- are perfectly positioned to fatten investors' pocketbooks.Though there are countless strategies to grow your wealth on Wall Street, few have proved as successful over the long run as buying and holding high-quality dividend stocks.Public companies that dole out a dividend to their shareholders on a regular basis tend to be recurringly profitable, time-tested, and are often capable of providing transparent long-term growth outlooks. In ...

When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get cut or suspended.Consider pharmaceutical giant Pfizer (PFE 3.38%). Its dividend yield is around 7.5% right now, and if the stock continues to decline, it may not be long before it hits 8%. The big question is whether ...

The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer (PFE 3.38%) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of safety concerns. Could Pfizer solve the issue by acquir ...

Pfizer (NYSE: PFE ) has sold off since my last update on the stock, but marginally outperformed the S&P 500 ( SPY ) ( SPX ) ( IVV ) ( VOO ) due to a tick up in the stock price in recent days:Providing alpha-generating investment ideas. I am an independent investor managing my family's portfolio, primarily via a Self Managed Super Fund. You can expect my articles to deliver a clearly structured, evidence-based thesis. But first and foremost, I encourage readers to judge me on my performance.I have a generali ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth treatment areas: and that's weight loss. Analysts forecast a compound annual growth rate in the double digits from today over the next several years, with the market reaching $100 billion to $130 billion in the early 2030s.Today, Eli Lilly and Novo Nordisk dominate with their well-known treatments: Lilly makes tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound fo ...

Pfizer's CEO said President Donald Trump's tariffs and uncertainty are holding the company back from making "tremendous investments" in the US. In a first-quarter earnings call on Tuesday, chief executive Albert Bourla was asked what incentives he would want to see in tariff negotiations that would make him increase manufacturing investments in the US."If I know that there will not be tariffs and a heavy certainty, then there are tremendous investments that can happen in this country, both in R&D and manuf ...

Key Takeaways Pfizer posted Q1 earnings of $0.92 per share, crushing EPS expectations of $0.64 by 43%. Trading near multi-year lows of $20 a share, investors may be eyeing Pfizer's stock for a continued rebound. Pfizer is on track to exceed its net cost savings targets amid declining revenue from COVID-related products.Pfizer (PFE)  shares spiked +3% in Tuesday’s trading session as the pharmaceutical giant was able to crush its Q1 earnings expectations this morning. Still, Pfizer stock has fallen 10% year ...

Pfizer (PFE) Q1 2025 Earnings Call April 29, 2025 03:42 PM ET Speaker0 Good day, everyone, and welcome to Pfizer's First Quarter twenty twenty five Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DiMartino, Chief Investment Relations Officer and Senior Vice President. Please go ahead, ma'am. Speaker1 Good morning, and welcome to Pfizer's earnings call. I'm Francesca DiMartino, Chief Investor Relations Officer. On behalf of the Pfizer te ...

文章核心观点 - 辉瑞CEO称特朗普计划征收的药品关税带来的不确定性，阻碍公司在美国制造业和研发领域进一步投资，公司希望关税谈判有确定性结果 [1][3] 关税对投资的影响 - 若确定无关税，公司将在美国研发和制造领域进行大量投资，当前不确定性下公司控制成本、谨慎投资 [3] - 全球最低税率约15%的设立使税收环境改变，但无额外激励或关税明确信息，美国投资吸引力不足 [4] - 特朗普若降低现行税收制度，特别是对本地生产商品的税收，将成为公司在美国制造的有力激励 [5] 公司业绩与关税成本 - 辉瑞未修订全年业绩展望，业绩指引未包含未来关税和贸易政策变化的潜在影响，但反映了特朗普现有关税带来的1.5亿美元成本 [6] - 公司在业绩指引范围内考虑了现有关税成本，即便有这些成本，仍趋向业绩指引范围上限 [7]

文章核心观点 - 辉瑞2025年第一季度财报表现喜忧参半，盈利超预期但销售额未达预期，公司重申2025年业绩指引，虽面临产品销售下滑、专利到期等挑战，但非新冠药物和成本削减措施有望推动增长 [15][16][20] 财务业绩 - 第一季度调整后每股收益92美分，同比增长12%，超扎克斯普遍预期的64美分 [1] - 营收137.2亿美元，同比下降8%，运营下降6%，货币影响为-2%，未达扎克斯普遍预期的138.9亿美元 [2] - 国际营收运营基础上增长4%至53.4亿美元，美国营收下降12%至83.7亿美元 [3] - 调整后销售、信息和行政费用运营上下降12%至30.1亿美元，调整后研发费用下降12%至21.7亿美元 [3] 各业务板块销售情况 初级护理 - 初级护理部门销售额运营上下降20%至57亿美元 [4] - 与百时美施贵宝合作的血液稀释剂艾乐妥收入下降4%至19.2亿美元，未达扎克斯普遍预期和模型估计 [5] - 沛儿全球系列收入下降1%至16.6亿美元，美国增长2%，国际市场下降6%，未达扎克斯普遍预期和模型估计 [6] - 与BioNTech合作的复必泰收入5.65亿美元，同比增长62%，超扎克斯普遍预期和估计 [7] - 帕罗维德收入4.91亿美元，同比下降75%，未达扎克斯普遍预期和模型估计 [8] - 努泰克ODT/Vydura贡献2.48亿美元，同比增长40% [8] - 呼吸道合胞病毒疫苗Abrysvo销售额1.31亿美元，同比下降6%，未达扎克斯普遍预期和模型估计 [9] 专科护理 - 专科护理部门销售额40亿美元，增长6% [4] - 维达全全球系列收入14.9亿美元，同比增长33%，超扎克斯普遍预期和模型估计 [10][11] - 尚杰销售额下降31%至1.28亿美元，恩利收入下降6%至1.4亿美元 [11] 肿瘤学 - 肿瘤学部门销售额增长7%至37.6亿美元 [4] - 2023年12月收购Seagen后，安适利销售额2.18亿美元，下降15%，Padcev增长25%至4.26亿美元，图卡替尼和替凡得分别贡献1.02亿美元和3300万美元 [12] - 爱博新收入下降6%至9.77亿美元，超扎克斯普遍预期和估计 [13] - 恩杂鲁胺联盟收入4.58亿美元，同比增长9%，英立达收入2.19亿美元，下降6%，劳拉替尼销售额增长39%至2.22亿美元 [13] 业绩指引 - 公司维持2025年业绩指引，预计总收入在610亿至640亿美元之间，调整后每股收益在2.80至3.00美元之间，研发费用在107亿至117亿美元之间，销售、信息和行政支出在133亿至143亿美元之间，调整后税率约为15% [14] 面临挑战与机遇 挑战 - 2025年面临新冠产品销售下滑和美国医疗保险D部分的不利影响，2026 - 2030年多款关键产品专利到期 [17] - 本月早些时候停止开发减肥药丸danuglipron [18] - 未提供未来关税和贸易政策变化潜在影响的估计，而强生和默克有相关预估 [19] 机遇 - 随着新冠相关不确定性减少，公司收入波动性下降，非新冠药物和新收购产品将推动2025年收入增长 [20] - 预计到2027年底成本削减和内部重组将节省77亿美元，非新冠销售增长和成本削减措施将推动利润增长 [20] 股票评级 - 辉瑞目前扎克斯评级为2（买入） [21]